| Date | Title | Description |
| 07.04.2026 | Efmody® (modified-release hydrocortisone) granted extension of indication for adrenal insufficiency | Efmody® (modified-release hydrocortisone) granted extension of indication for adrenal insufficiency
Tue, Apr 07, 2026 09:00 CET Report this content
Stockholm, Sweden – April 7, 2026 - Immedica Pharma AB is pleased to announce that the Europ... |
| 01.04.2026 | Immedica announces first marketing authorization approval in the MENA region for Ztalmy® (ganaxolone) for CDKL5 deficiency disorder | Immedica announces first marketing authorization approval in the MENA region for Ztalmy® (ganaxolone) for CDKL5 deficiency disorder
Wed, Apr 01, 2026 13:19 CET Report this content
Stockholm, Sweden, April 1, 2026 – Immedica today announced ... |
| 27.03.2026 | Zepzelca® (lurbinectedin) in combination with atezolizumab receives positive CHMP opinion as first-line maintenance therapy for extensive-stage small cell lung cancer | Zepzelca® (lurbinectedin) in combination with atezolizumab receives positive CHMP opinion as first-line maintenance therapy for extensive-stage small cell lung cancer
Fri, Mar 27, 2026 14:30 CET Report this content
Stockholm, Sweden, March ... |
| 04.03.2026 | Ravicti® (glycerol phenylbutyrate) approved in United Arab Emirates and Sultanate of Oman | Ravicti® (glycerol phenylbutyrate) approved in United Arab Emirates and Sultanate of Oman
Wed, Mar 04, 2026 09:30 CET Report this content
Stockholm, March 4, 2026 - Immedica today announced that Ravicti® (glycerol phenylbutyrate) has receiv... |
| 23.02.2026 | U.S. FDA has granted accelerated approval of Loargys® (pegzilarginase-nbln) for the treatment of hyperargininemia in patients 2 years and older with arginase 1 deficiency (ARG1-D) | U.S. FDA has granted accelerated approval of Loargys® (pegzilarginase-nbln) for the treatment of hyperargininemia in patients 2 years and older with arginase 1 deficiency (ARG1-D)
Mon, Feb 23, 2026 20:09 CET Report this content
STOCKHOLM, S... |
| 02.02.2026 | Immedica announces positive results from phase 3 study of Loargys® (pegzilarginase) in patients below 2 years | Immedica announces positive results from phase 3 study of Loargys® (pegzilarginase) in patients below 2 years
Mon, Feb 02, 2026 14:00 CET Report this content
Stockholm, Sweden, Februari 2, 2026 – Immedica today announces the results from a ... |
| 25.01.2026 | Immedica Completes Major Rare Disease Acquisition, Expands Global Endocrinology Footprint | Immedica Pharma finalized its $65 million acquisition of Neurocrine Group Limited. This strategic move adds Alkindi and Efmody, critical hydrocortisone therapies for rare adrenal conditions, to Immedica's portfolio. The deal establishes rar... |
| 21.01.2026 | Immedica completes acquisition of Neurocrine Group Limited, Neurocrine Biosciences’ European rare commercial business | Immedica completes acquisition of Neurocrine Group Limited, Neurocrine Biosciences’ European rare commercial business
Wed, Jan 21, 2026 15:45 CET Report this content
Portfolio includes global rights to Alkindi® (hydrocortisone) and global r... |
| 14.01.2026 | Immedica announces FDA acceptance of pegzilarginase BLA resubmission in the U.S. | Immedica announces FDA acceptance of pegzilarginase BLA resubmission in the U.S.
Wed, Jan 14, 2026 15:00 CET Report this content
Stockholm, Sweden, January 14, 2026, - Immedica Pharma AB today announced that the U.S. Food and Drug Administr... |
| 08.01.2026 | Immedica to acquire Neurocrine Group Limited, Neurocrine Biosciences’ European rare commercial business | Immedica to acquire Neurocrine Group Limited, Neurocrine Biosciences’ European rare commercial business
Thu, Jan 08, 2026 18:00 CET Report this content
Portfolio includes global rights to Alkindi® (hydrocortisone) and global rights ex-US to... |
| 22.12.2025 | Immedica and OrphanPacific announce approval of Ravicti® (glycerol phenylbutyrate) in Japan for the treatment of UCDs | Immedica and OrphanPacific announce approval of Ravicti® (glycerol phenylbutyrate) in Japan for the treatment of UCDs
Mon, Dec 22, 2025 10:30 CET Report this content
Stockholm, December 22, 2025 - Immedica and its partner OrphanPacific, Inc... |
| 10.12.2025 | Loargys® (pegzilarginase) granted marketing authorization in Oman for the treatment of arginase 1 deficiency (ARG1-D) | Loargys® (pegzilarginase) granted marketing authorization in Oman for the treatment of arginase 1 deficiency (ARG1-D)
Wed, Dec 10, 2025 10:00 CET Report this content
Stockholm, Sweden, December 10, 2025 – Immedica today announces that Loarg... |
| 09.12.2025 | Immedica submits pegzilarginase application to the Australian Therapeutic Goods Administration (TGA) | Immedica submits pegzilarginase application to the Australian Therapeutic Goods Administration (TGA)
Tue, Dec 09, 2025 17:00 CET Report this content
Stockholm, Sweden, December 9, 2025 – Immedica today announced that it has submitted a pres... |
| 28.11.2025 | Zepzelca® (lurbinectedin) in combination with atezolizumab approved as first-line maintenance therapy for extensive-stage small cell lung cancer in United Arab Emirates (UAE) | Zepzelca® (lurbinectedin) in combination with atezolizumab approved as first-line maintenance therapy for extensive-stage small cell lung cancer in United Arab Emirates (UAE)
Fri, Nov 28, 2025 14:33 CET Report this content
Stockholm, Sweden... |
| 31.10.2025 | Immedica submits New Drug Submission (NDS) for Loargys® (pegzilarginase) to Health Canada | Immedica submits New Drug Submission (NDS) for Loargys® (pegzilarginase) to Health Canada
Fri, Oct 31, 2025 12:00 CET Report this content
Stockholm, Sweden, October 31, 2025 – Immedica today announced that the submitted New Drug Submission ... |
| 12.10.2025 | CVC: €10.4 Billion Raised For European Direct Lending Strategy | CVC Credit, the global credit management subsidiary of the investment firm CVC, has recently announced the final closing of its fourth European Direct Lending fund, referred to as EUDL IV. This fund has raised €10.4 billion, which will be d... |
| 01.10.2025 | Immedica and Innovative Medicines Group enter agreement on Loargys® (pegzilarginase) in Latin America | Immedica and Innovative Medicines Group enter agreement on Loargys® (pegzilarginase) in Latin America
Wed, Oct 01, 2025 11:00 CET Report this content
Stockholm, Sweden, October 1, 2025 – Immedica has entered into an agreement with Innovativ... |
| 29.08.2025 | Immedica Publishes Favorable Long-Term Data on Loargys® (pegzilarginase) | Immedica Publishes Favorable Long-Term Data on Loargys® (pegzilarginase)
Fri, Aug 29, 2025 10:00 CET Report this content
Stockholm, August 29, 2025 – Immedica is pleased to announce the publication of favorable long-term data on Loargys (pe... |
| 18.08.2025 | Ravicti® (glycerol phenylbutyrate) approved in Saudi Arabia, Qatar and Kuwait | Ravicti® (glycerol phenylbutyrate) approved in Saudi Arabia, Qatar and Kuwait
Mon, Aug 18, 2025 12:00 CET Report this content
Stockholm, August 18, 2025 Immedica is pleased to announce that Ravicti® (glycerol phenylbutyrate) has received re... |
| 05.08.2025 | iBIO Releases Inaugural Member Investor Portfolio Report Showcasing $1.24 Billion in Illinois Life Sciences Investment | Report highlights nearly 100 life science companies and investment trends as Chicago prepares to welcome BIO International Convention 2030
CHICAGO, Aug. 5, 2025 /PRNewswire-PRWeb/ -- The Illinois Biotechnology Innovation Organization (iBIO)... |
| 30.07.2025 | KKR: Majority Stake In HealthCare Royalty Partners Acquired | Global investment firm KKR has acquired a majority stake in HealthCare Royalty Partners (HCRx), enhancing its capabilities in biopharma royalty and credit investing.
Founded in 2006 and based in Stamford, Connecticut, HCRx is a premier biop... |
| 25.06.2025 | Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties | Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
Wed, Jun 25, 2025 14:02 CET Report this content
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Roya... |
| 17.06.2025 | Immedica regains commercial rights in the MENA region for Ztalmy® (ganaxolone) | Immedica regains commercial rights in the MENA region for Ztalmy® (ganaxolone)
Tue, Jun 17, 2025 14:00 CET Report this content
Stockholm, Sweden – June 12, 2025 – Immedica today announces that the company and its partner Biologix FZCo have ... |
| 12.06.2025 | Immedica MAH for Ztalmy® (ganaxolone) in the EU | Immedica MAH for Ztalmy® (ganaxolone) in the EU
Thu, Jun 12, 2025 10:00 CET Report this content
Stockholm, Sweden – June 12, 2025 – Immedica Pharma AB today announced that Immedica became the Marketing Authorisation Holder (MAH) for the orp... |
| 18.05.2025 | The Real Estate Tug-of-War: PHP's Bold Move for Assura | In the world of real estate investment trusts (REITs), competition can be fierce. The latest skirmish involves Primary Health Properties (PHP) and Assura, two players in the healthcare property sector. PHP has made a surprising third bid fo... |
| 13.05.2025 | Immedica Publishes Annual & Sustainability Report for 2024 | Immedica Publishes Annual & Sustainability Report for 2024
Tue, May 13, 2025 15:12 CET Report this content
Stockholm, Sweden – May 13, 2025 – Immedica today announces the publication of its Annual & Sustainability Report for 2024, h... |
| 25.04.2025 | The Power of Workplace Culture: A Deep Dive into Employee Satisfaction | In the corporate world, workplace culture is the invisible thread that binds employees to their organizations. It shapes experiences, drives performance, and ultimately determines success. Recent accolades for companies like Linxon Americas... |
| 25.04.2025 | Immedica ranked Top 2 among Sweden’s Best Workplaces™ 2025 | Immedica ranked Top 2 among Sweden’s Best Workplaces™ 2025
Fri, Apr 25, 2025 10:00 CET Report this content
Stockholm, April 25 , 2025 – Immedica has earned a Top 2 ranking among Sweden’s Best Workplaces™ 2025, awarded by Great Place to Work... |
| 10.04.2025 | Immedica Strengthens Focus on Rare Diseases with New Therapeutic Area | Immedica Strengthens Focus on Rare Diseases with New Therapeutic Area
Thu, Apr 10, 2025 11:32 CET Report this content
Stockholm, April 10, 2025 – Immedica continues to expand its presence in the rare disease space by introducing a new Thera... |
| 11.02.2025 | Immedica completes acquisition of Marinus Pharmaceuticals, Inc. | Immedica completes acquisition of Marinus Pharmaceuticals, Inc.
Tue, Feb 11, 2025 14:35 CET Report this content
Stockholm, Sweden – February 11, 2025 – Immedica Pharma AB (“Immedica”), a leading global rare disease company, announced today ... |
| 07.02.2025 | Immedica successfully completes tender offer for all outstanding shares of common stock of Marinus Pharmaceuticals, Inc. | Immedica successfully completes tender offer for all outstanding shares of common stock of Marinus Pharmaceuticals, Inc.
Fri, Feb 07, 2025 12:35 CET Report this content
Stockholm, Sweden – February 7, 2025 – Immedica Pharma AB (“Immedica”),... |
| 09.01.2025 | Highway to Investment: KKR and OTPP Drive into India's Infrastructure | In the bustling world of finance, highways are more than just asphalt and concrete. They are lifelines, connecting cities, economies, and opportunities. Recently, two titans of investment, KKR and the Ontario Teachers’ Pension Plan (OTPP), ... |
| 08.01.2025 | Immedica to commence tender offer for all outstanding shares of common stock of Marinus Pharmaceuticals, Inc. | Immedica to commence tender offer for all outstanding shares of common stock of Marinus Pharmaceuticals, Inc.
Wed, Jan 08, 2025 22:05 CET Report this content
Stockholm, Sweden – January 8, 2025 – Immedica Pharma AB (“Immedica”), a leading g... |
| 30.12.2024 | Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals, Inc. | Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals, Inc.
Mon, Dec 30, 2024 13:00 CET Report this content
Stockholm, Sweden and Radnor, Pa. – December 30, 2024 - Immedica Pharma AB (Immedica), a leading global rare disease... |
| 27.12.2024 | Application to the Ministry of Health in Japan for Ravicti® (Glycerol Phenylbutyrate) submitted | Application to the Ministry of Health in Japan for Ravicti® (Glycerol Phenylbutyrate) submitted
Fri, Dec 27, 2024 09:30 CET Report this content
Stockholm, December 27, 2024 – Immedica is pleased to announce that its partner OrphanPacific, I... |
| 11.11.2024 | Immedica's Strategic Leap: A New Era with Benjamin Owens | In the world of pharmaceuticals, change is the only constant. Immedica, a rising star in the rare disease therapeutics arena, has made a bold move by appointing Benjamin Owens as its new Executive Vice President and Head of Corporate Develo... |
| 11.11.2024 | Immedica welcomes Benjamin Owens as Head of Corporate Development | Immedica welcomes Benjamin Owens as Head of Corporate Development
Mon, Nov 11, 2024 09:40 CET Report this content
Stockholm, November 11, 2024 – Immedica is pleased to announce that Benjamin Owens, Ph.D. has joined the company as Executive ... |
| 05.11.2024 | BLA for pegzilarginase in the treatment of arginase 1 deficiency (ARG1-D) accepted for priority review by the U.S. FDA | BLA for pegzilarginase in the treatment of arginase 1 deficiency (ARG1-D) accepted for priority review by the U.S. FDA
Tue, Nov 05, 2024 17:00 CET Report this content
Stockholm, November 5, 2024: Immedica announces today that the Biologics ... |
| 25.10.2024 | Data from the phase 3 SIERRA trial of Iomab-B presented at the annual European Association of Nuclear Medicine (EANM) Congress 2024 | Data from the phase 3 SIERRA trial of Iomab-B presented at the annual European Association of Nuclear Medicine (EANM) Congress 2024
Fri, Oct 25, 2024 11:30 CET Report this content
Stockholm, October 25, 2024 – Immedica is pleased to announc... |
| 25.09.2024 | Immedica publishes key study on societal impact of ARG1-D | Immedica publishes key study on societal impact of ARG1-D
Wed, Sep 25, 2024 11:00 CET Report this content
Stockholm, September 25, 2024 – Immedica is pleased to announce the publication of its sponsored study, "Societal Costs and Quali... |
| 24.09.2024 | Joe Whalen joins Immedica’s Business development team | Joe Whalen joins Immedica’s Business development team
Tue, Sep 24, 2024 09:45 CET Report this content
Stockholm, September 24, 2024 – Immedica is excited to announce that Joe Whalen has joined its business development team. Joe brings over ... |
| 20.09.2024 | Joint acquisition of Immedica Pharma completed | Joint acquisition of Immedica Pharma completed
Fri, Sep 20, 2024 08:00 CET Report this content
Stockholm, September 20, 2024 – KKR, a leading global investment firm, and Impilo, a Nordic healthcare investment firm, have today announced the ... |
| 18.09.2024 | Immedica Pharma: A New Era in Rare Disease Treatment | Immedica Pharma is making waves in the pharmaceutical industry. With a focus on rare diseases, the company is poised for significant growth. Recent leadership changes and clinical advancements signal a promising future.
On September 17, 202... |
| 18.09.2024 | Immedica initiates a phase 3 pediatric study for Loargys® (pegzilarginase) in arginase 1 deficiency | Immedica initiates a phase 3 pediatric study for Loargys® (pegzilarginase) in arginase 1 deficiency
Wed, Sep 18, 2024 14:45 CET Report this content
Stockholm, September 18, 2024: Immedica announces today that the first subject has been dose... |
| 17.09.2024 | Immedica appoints Daniel Camardo as President of Immedica North America | Immedica appoints Daniel Camardo as President of Immedica North America
Tue, Sep 17, 2024 13:00 CET Report this content
Stockholm, September 17, 2024 – Immedica Pharma AB announces today the appointment of Daniel Camardo as President of Imm... |
| 09.09.2024 | Immedica expands into the U.S., establishes Chicago-based commercial business | Immedica expands into the U.S., establishes Chicago-based commercial business
Mon, Sep 09, 2024 12:00 CET Report this content
Stockholm, September 9, 2024 – Immedica Pharma AB, a global pharmaceutical company dedicated to addressing rare an... |
| 03.09.2024 | Immedica presents new data highlighting treatment benefits of Loargys® (pegzilarginase) in arginase 1 deficiency at the SSIEM congress | Immedica presents new data highlighting treatment benefits of Loargys® (pegzilarginase) in arginase 1 deficiency at the SSIEM congress
Tue, Sep 03, 2024 11:00 CET Report this content
Stockholm, September 3, 2024: Immedica announces today th... |
| 15.06.2024 | Immedica’s partner Actinium announces Iomab-B phase 3 SIERRA trial results in patients with TP53 mutation at the EHA 2024 Annual Congress | Immedica’s partner Actinium announces Iomab-B phase 3 SIERRA trial results in patients with TP53 mutation at the EHA 2024 Annual Congress
Sat, Jun 15, 2024 17:30 CET Report this content
Stockholm, June 15, 2024 - Immedica’s partner Actinium... |
| 26.04.2024 | Immedica announces publication of 2023 Business Review and Annual & Sustainability Report | Immedica announces publication of 2023 Business Review and Annual & Sustainability Report
Fri, Apr 26, 2024 13:15 CET Report this content
Stockholm, April 26, 2024 – Immedica is proud to announce the release of our Business Review and A... |
| 23.04.2024 | Leading global investment firm KKR and Nordic healthcare investment firm Impilo enters strategic partnership together with Immedica management | Leading global investment firm KKR and Nordic healthcare investment firm Impilo enters strategic partnership together with Immedica management
Tue, Apr 23, 2024 07:15 CET Report this content
Stockholm, April 23, 2024 –Investment funds manag... |
| 19.04.2024 | Immedica recognized as one of Sweden’s Best Workplaces 2024 by Great Place To Work® | Immedica recognized as one of Sweden’s Best Workplaces 2024 by Great Place To Work®
Fri, Apr 19, 2024 09:40 CET Report this content
Stockholm, April 19, 2024 – Immedica has made the list of Sveriges Bästa Arbetsplatser™ (Sweden's Best Workp... |
| 18.04.2024 | Immedica’s partner Actinium announces Iomab-B phase 3 SIERRA trial results in patients with a TP53 mutation presented in an oral presentation at the 50th EBMT annual meeting | Immedica’s partner Actinium announces Iomab-B phase 3 SIERRA trial results in patients with a TP53 mutation presented in an oral presentation at the 50th EBMT annual meeting
Thu, Apr 18, 2024 10:15 CET Report this content
Stockholm, April 1... |
| 21.03.2024 | Ravicti® (glycerol phenylbutyrate) approved by the Taiwan Food and Drug Administration (TFDA) for the treatment of Urea Cycle Disorders | Ravicti® (glycerol phenylbutyrate) approved by the Taiwan Food and Drug Administration (TFDA) for the treatment of Urea Cycle Disorders
Thu, Mar 21, 2024 12:15 CET Report this content
Stockholm, March 21, 2024 – Immedica and its partner Win... |
| 29.02.2024 | From anonymity to recognition: The challenge of underdiagnosis and misdiagnosis in rare diseases | From anonymity to recognition: The challenge of underdiagnosis and misdiagnosis in rare diseases
Thu, Feb 29, 2024 08:00 CET Report this content
As we highlight Rare Disease Day, it’s crucial to focus on the often-overlooked issue of underd... |
| 27.02.2024 | Immedica’s partner Actinium presented four abstracts of Iomab-B at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® | Immedica’s partner Actinium presented four abstracts of Iomab-B at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Tue, Feb 27, 2024 08:00 CET Report this content
Stockholm, February 27, 2024... |
| 22.12.2023 | Loargys® (pegzilarginase) approved in Great Britain for treatment of arginase 1 deficiency (ARG1-D) | Loargys® (pegzilarginase) approved in Great Britain for treatment of arginase 1 deficiency (ARG1-D)
Fri, Dec 22, 2023 10:15 CET Report this content
Stockholm, 21, 2023: Immedica today announces that the Medicines & Healthcare products R... |
| 21.12.2023 | Immedica intends to re-submit the BLA seeking approval of Loargys® (pegzilarginase) for treatment of arginase 1 deficiency (ARG1-D) in the US | Immedica intends to re-submit the BLA seeking approval of Loargys® (pegzilarginase) for treatment of arginase 1 deficiency (ARG1-D) in the US
Thu, Dec 21, 2023 11:00 CET Report this content
Stockholm, December 21, 2023: Immedica today annou... |
| 18.12.2023 | Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D) | Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D)
Mon, Dec 18, 2023 15:15 CET Report this content
Stockholm, December 18, 2023: Immedica today announces that the European Commission has granted mar... |
| 14.11.2023 | Immedica’s partner Actinium announces oral presentation at ASH annual meeting on Iomab-B outcomes data for TP53 gene mutation from the SIERRA trial | Immedica’s partner Actinium announces oral presentation at ASH annual meeting on Iomab-B outcomes data for TP53 gene mutation from the SIERRA trial
Tue, Nov 14, 2023 14:30 CET Report this content
Stockholm, November 14 , 2023 – Immedica’s p... |
| 20.10.2023 | Glycerol phenylbutyrate granted orphan drug designation for treatment of STXBP1 developmental and epileptic encephalopathy | Glycerol phenylbutyrate granted orphan drug designation for treatment of STXBP1 developmental and epileptic encephalopathy
Fri, Oct 20, 2023 10:00 CET Report this content
Stockholm, October 20, 2023 – Immedica today announces that the Europ... |
| 13.10.2023 | Loargys® (pegzilarginase) receives positive opinion by the CHMP for treatment of arginase 1 deficiency | Loargys® (pegzilarginase) receives positive opinion by the CHMP for treatment of arginase 1 deficiency
Fri, Oct 13, 2023 13:40 CET Report this content
Stockholm, October 13, 2023: Immedica today announces that the Committee for Medicinal Pr... |
| 29.09.2023 | Ravicti® (glycerol phenylbutyrate) approved by the National Administration of Drugs, Food and Medical Devices in Argentina for treatment of urea cycle disorders | Ravicti® (glycerol phenylbutyrate) approved by the National Administration of Drugs, Food and Medical Devices in Argentina for treatment of urea cycle disorders
Fri, Sep 29, 2023 09:30 CET Report this content
Stockholm, September 29, 2023 –... |
| 28.08.2023 | Immedica to present new pegzilarginase data at the SSIEM Annual Symposium 2023 | Immedica to present new pegzilarginase data at the SSIEM Annual Symposium 2023
Mon, Aug 28, 2023 14:00 CET Report this content
Stockholm, August 28, 2023 Immedica today announces the presentation of new data at the SSIEM (Society for the St... |
| 25.08.2023 | I131-apamistamab SIERRA abstracts accepted for oral and poster presentation at the European Association of Nuclear Medicine 2023 Congress | I131-apamistamab SIERRA abstracts accepted for oral and poster presentation at the European Association of Nuclear Medicine 2023 Congress
Fri, Aug 25, 2023 08:00 CET Report this content
Stockholm, August 25, 2023 – Immedica’s partner Actini... |
| 27.07.2023 | Immedica acquires global rights to pegzilarginase from Aeglea | Immedica acquires global rights to pegzilarginase from Aeglea
Thu, Jul 27, 2023 13:05 CET Report this content
Stockholm, July 27, 2023 – Immedica announces that it has signed an agreement to acquire the global rights to pegzilarginase and r... |
| 21.07.2023 | Zepzelca® (lurbinectedin) approved by the Ministry of Health in Oman for the treatment of metastatic Small Cell Lung Cancer | Zepzelca® (lurbinectedin) approved by the Ministry of Health in Oman for the treatment of metastatic Small Cell Lung Cancer
Fri, Jul 21, 2023 13:15 CET Report this content
Stockholm, July 21, 2023 – Immedica’s product Zepzelca® (lurbinected... |
| 21.06.2023 | Glycerol phenylbutyrate approved by the National Medical Products Administration in China for the treatment of Urea Cycle Disorders | Glycerol phenylbutyrate approved by the National Medical Products Administration in China for the treatment of Urea Cycle Disorders
Wed, Jun 21, 2023 07:30 CET Report this content
Stockholm, June 21, 2023 – Immedica’s partner Hongkong WinHe... |
| 15.05.2023 | Iomab-B SIERRA trial results accepted for oral presentation at the European Hematology Association 2023 Congress | Iomab-B SIERRA trial results accepted for oral presentation at the European Hematology Association 2023 Congress
Mon, May 15, 2023 11:19 CET Report this content
Stockholm, May 15 , 2023 – Immedica’s partner Actinium Pharmaceuticals, Inc. ha... |
| 26.04.2023 | Immedica publishes Business Review and Annual & Sustainability report 2022 | Immedica publishes Business Review and Annual & Sustainability report 2022
Wed, Apr 26, 2023 10:35 CET Report this content
Stockholm, April 26 , 2023 - Immedica has today published its Business review and Annual & Sustainability rep... |
| 21.04.2023 | Immedica’s partner OrphanPacific initiates phase 3 trial with glycerol phenylbutyrate for treatment of urea cycle disorders in Japan | Immedica’s partner OrphanPacific initiates phase 3 trial with glycerol phenylbutyrate for treatment of urea cycle disorders in Japan
Fri, Apr 21, 2023 14:15 CET Report this content
Stockholm, April 21 , 2023 - Immedica’s partner OrphanPacif... |
| 23.02.2023 | Positive results from the pivotal phase 3 SIERRA trial in patients with relapsed or refractory acute myeloid leukemia | Positive results from the pivotal phase 3 SIERRA trial in patients with relapsed or refractory acute myeloid leukemia
Thu, Feb 23, 2023 10:37 CET Report this content
Stockholm, February 23, 2023 - Immedica’s partner Actinium Pharmaceuticals... |
| 24.01.2023 | Helsinn and Immedica enter exclusive partnership for commercialization of cancer supportive care products in core European markets | Helsinn and Immedica enter exclusive partnership for commercialization of cancer supportive care products in core European markets
Tue, Jan 24, 2023 09:00 CET Report this content
LUGANO, Switzerland and STOCKHOLM, Sweden – January 24, 2023 ... |
| 01.09.2021 | Pharma Mar S A : PharmaMar announces the approval of Zepzelca® (lurbinectedin) for the treatment of metastatic Small Cell Lung Cancer in the United Arab Emirates | PharmaMar announces the approval of
Zepzelca® (lurbinectedin) for the treatment of
metastatic Small Cell Lung Cancer in the
United Arab Emirates
This approval is based on overall response rate and duration of response, demonstrated in the o... |
